Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022
Research

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

Aharona Glatman-FreedmanComments to Author , Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, and Lital Keinan-Boker
Author affiliations: Tel Aviv University School of Public Health, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (A. Glatman-Freedman, M. Bromberg, Y. Hershkovitz, H. Sefty, Z. Kaufman, R. Dichtiar, L. Keinan-Boker); Haifa University School of Public Health, Haifa, Israel (L. Keinan-Boker)

Main Article

Figure 1

Estimations of effectiveness of BNT162b2 vaccine booster (Pfizer, https://www.pfizer.com) against SARS-CoV-2 infection and breakthrough complications, Israel. A) Epidemic curve of new PCR-confirmed SARS-CoV-2–positive persons, June 1, 2021–January 1, 2022. Index dates are highlighted in orange (for persons >60 years of age) and light blue (for persons 16–59 years of age). B) Daily booster dose recipients by age group. C) Graphic illustration of the booster dose vaccine effectiveness evaluation method for a single cohort of persons >60 years of age that received the booster dose on August 1, 2021. Orange bars represent the number of persons who received the booster dose each day; light blue asterisk represents the date persons >60 years of age included in cohort 1 received the booster dose. D) Graphic illustration of the booster dose vaccine effectiveness evaluation method for a single cohort of persons 16–59 years of age who received the booster dose on August 29, 2021. Light blue bars represent the number of persons who received the booster dose each day; orange asterisk represents the date persons 16–59 years of age included in cohort 1 received the booster dose.

Figure 1. Estimations of effectiveness of BNT162b2 vaccine booster (Pfizer, https://www.pfizer.com) against SARS-CoV-2 infection and breakthrough complications, Israel. A) Epidemic curve of new PCR-confirmed SARS-CoV-2–positive persons, June 1, 2021–January 1, 2022. Index dates are highlighted in orange (for persons >60 years of age) and light blue (for persons 16–59 years of age). B) Daily booster dose recipients by age group. C) Graphic illustration of the booster dose vaccine effectiveness evaluation method for a single cohort of persons >60 years of age that received the booster dose on August 1, 2021. Orange bars represent the number of persons who received the booster dose each day; light blue asterisk represents the date persons >60 years of age included in cohort 1 received the booster dose. D) Graphic illustration of the booster dose vaccine effectiveness evaluation method for a single cohort of persons 16–59 years of age who received the booster dose on August 29, 2021. Light blue bars represent the number of persons who received the booster dose each day; orange asterisk represents the date persons 16–59 years of age included in cohort 1 received the booster dose.

Main Article

Page created: March 18, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external